Having trouble accessing articles? Reset your cache.

Spero's TB program first licensing deal for Gates Medical Research Institute

A partnership to develop Spero's Phase I compound for tuberculosis is the first licensing deal announced by Gates

Read the full 185 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE